Obinepitide

Drug Profile

Obinepitide

Alternative Names: TM 30338

Latest Information Update: 07 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 7TM Pharma
  • Class Anorectics; Hormones; Obesity therapies
  • Mechanism of Action Neuropeptide Y2 receptor agonists; Neuropeptide Y4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 12 Jun 2007 Phase-II clinical trials in Obesity in Sweden (SC)
  • 09 May 2006 Phase I/II clinical studies of TM 30338 have been completed in diabetes
  • 07 Jul 2005 Phase-I/II clinical trials in Obesity in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top